<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53723">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02000531</url>
  </required_header>
  <id_info>
    <org_study_id>ML29028</org_study_id>
    <nct_id>NCT02000531</nct_id>
  </id_info>
  <brief_title>A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>ENSURE Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva) and Erlotinib After Disease Progression in Chinese Population Enrolled in the ENSURE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>People&amp;apos;s Republic of China: CFDA</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an extension to ENSURE, a study of Tarceva (erlotinib) versus
      gemcitabine/cisplatin combination chemotherapy (GP) as the first-line treatment for patients
      with non-small cell lung cancer (NSCLC) with mutations in the tyrosine kinase domain of
      EGFR.

      This study is designed to examine the efficacy of Tarceva versus GP as a second-line
      treatment in NSCLC patients from the ENSURE trial. Patients previously treated with GP will
      be given Tarceva (150 mg orally) daily until disease progression or unacceptable toxicity
      occurs. Patients previously treated with Tarceva will be given cisplatin (75 mg/m2
      intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m2 IV) on Days 1 and 8 of 3-week
      chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles
      (whichever comes first).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival (PFS), defined as time from randomization until either disease progression on second-line treatment or death from any cause after disease progression on first-line treatment.</measure>
    <time_frame>Approximately 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Approximately 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Tarceva (Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine/cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib [Tarceva]</intervention_name>
    <description>150 mg oral dose given once daily. Given as second-line treatment at investigator's discretion after disease progression in ENSURE trial.</description>
    <arm_group_label>Tarceva (Erlotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>A 1250 mg/m2 intravenous infusion on Days 1 and 8 of each 3-week cycle, until disease progression, unacceptable toxicity or up to 4 cycles, whichever comes first. Given as second-line treatment at investigator's discretion after disease progression in ENSURE trial.</description>
    <arm_group_label>gemcitabine/cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>A 75 mg/m2 intravenous infusion on Day 1 of each 3-week cycle, until disease progression, unacceptable toxicity or up to 4 cycles, whichever comes first. Given as second-line treatment at investigator's discretion after disease progression in ENSURE trial.</description>
    <arm_group_label>gemcitabine/cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant in ENSURE trial

          -  Disease progression during first-line treatment

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML29028 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shantou</city>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
